NeuroSense Therapeutics Ltd. reported positive biomarker findings from its Phase 2 RoAD proof-of-concept study evaluating PrimeC for the treatment of Alzheimer’s disease. The announcement was made via a press release on June 25, 2026. NeuroSense is a biopharmaceutical company focused on developing therapies for neurological disorders.
